UPDATE: Taro Pharma (TARO) Reports Q1 EPS of $2.59
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Taro Provides Results for Quarter Ended June 2016
August 10, 2016 5:12 PM EDTHAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter ended June 30, 2016.
Quarter ended June 30, 2016 Highlights - compared to June 30, 2015
Net sales of $233.8 million, increased $18.5 million or 8.6%, with slightly decreased volumes. The 2015 net sales were negatively impacted by a $14 million provision for price protections. Gross profit of $182.8 million, increased $11.0 million Research and development (R&D) expenses increased 23.2% to $17.9 million Selling, marketing, general and administrative expenses were slightly decreased... More